Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 1:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Asymptomatic Myeloma Clear all
Active, not recruiting Early Phase 1 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

NCT04370483
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Leflunomide, Quality-of-Life Assessment
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

NCT01884688
View directory record Official record
Conditions
Asymptomatic Multiple Myeloma
Interventions
ENK Cell Infusion
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Phase 1 Interventional

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

NCT02697383
View directory record Official record
Conditions
Multiple Myeloma, High Risk Smoldering Multiple Myeloma
Interventions
Ixazomib (MLN9708), Dexamethasone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Sep 15, 2026, 1:01 AM EDT
Recruiting No phase listed Observational

Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies

NCT05136807
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma

NCT01222286
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
IPH2101
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

NCT01441973
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Elotuzumab (BMS-901608; HuLuc63)
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
12
States / cities
San Diego, California • New Haven, Connecticut • West Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 15, 2026, 1:01 AM EDT
Completed No phase listed Observational

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

NCT00919139
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Myeloma, Waldenstrom's Macroglobulinemia, Monoclonal Gammopathy of Undetermined Significance, Amyloidosis
Interventions
biologic sample preservation procedure
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
207
States / cities
Little Rock, Arkansas • Berkeley, California • Burlingame, California + 141 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Phase 1 Interventional Results available

Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma

NCT02492750
View directory record Official record
Conditions
Indolent Plasma Cell Myeloma, Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions
Anakinra, Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Placebo
Biological · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Sep 15, 2026, 1:01 AM EDT
Active, not recruiting Phase 2 Interventional

Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)

NCT02960555
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Isatuximab, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
3
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Active, not recruiting No phase listed Observational

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

NCT01177527
View directory record Official record
Conditions
Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
Interventions
Not listed
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Terminated Phase 1 Interventional

Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma

NCT02784483
View directory record Official record
Conditions
Asymptomatic Myeloma
Interventions
Atezolizumab (1200mg via IV infusion)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Sep 15, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

NCT01248455
View directory record Official record
Conditions
Multiple Myeloma, Myeloma, Smoldering Multiple Myeloma
Interventions
(Anti-KIR)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Sep 15, 2026, 1:01 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

NCT02886065
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Hiltonol, Citarinostat, Lenalidomide, PVX-410
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Phase 2 Interventional Results available

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394
View directory record Official record
Conditions
Smoldering Myeloma, Smoldering Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
9
States / cities
Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 15, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

NCT01302366
View directory record Official record
Conditions
Myeloma
Interventions
TBL12
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 15, 2026, 1:01 AM EDT
Recruiting No phase listed Observational

Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma

NCT02726750
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Not listed Phase 1 Interventional

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

NCT02240537
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Smoldering Multiple Myeloma (sMM)
Interventions
Sargramostim, BB-MPI-03, Montanide
Drug
Lead sponsor
Benovus Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Sep 15, 2026, 1:01 AM EDT
Recruiting No phase listed Observational

Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions

NCT05361694
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Terminated Phase 2 Interventional Results available

Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

NCT00983346
View directory record Official record
Conditions
Cancer, Myeloma, Multiple Myeloma
Interventions
Bortezomib
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 15, 2026, 1:01 AM EDT
Recruiting Not applicable Interventional

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

NCT07446777
View directory record Official record
Conditions
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet, Supportive Materials
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Recruiting No phase listed Observational

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

NCT06212323
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Active, not recruiting Phase 2 Interventional

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

NCT05014646
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Cholestyramine, Leflunomide
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Duarte, California • Detroit, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 15, 2026, 1:01 AM EDT
Completed Early Phase 1 Interventional

Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

NCT03631043
View directory record Official record
Conditions
Smoldering Plasma Cell Myeloma
Interventions
Biopsy Specimen Radiography, Lenalidomide, Vaccine Therapy
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 15, 2026, 1:01 AM EDT
Active, not recruiting Phase 2 Interventional

CAR- PRISM (PRecision Intervention Smoldering Myeloma)

NCT05767359
View directory record Official record
Conditions
Multiple Myeloma, Smoldering Multiple Myeloma
Interventions
Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2040
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 15, 2026, 1:01 AM EDT